expanded at a slower pace compared with the same period last year due to a contraction in merchandise exports resulting from uncertainty in the trade policies of major countries and the Baht’s ongoing
Bangchak Corporation Plc. I 3 Executive Summary Summary of the Company and its subsidiaries’ operating results for the quarter ended 30th September 2019 Unit: THB Million Q3/2019 Q2/2019 QoQ Q3/2018 YoY
No. Tor Thor. 35/2556 Re: Standard Conduct of Business, Management Arrangement, Operating Systems, and Providing Services to Clients of Securities Companies and Derivatives Intermediaries dated 6
55.33 (43.10) (43.79%) Gross profit 559.94 488.25 (71.68) (12.80%) Other income 20.48 9.54 (10.94) (53.41%) Selling and administrative expenses 96.21 93.90 (2.31) (2.40%) Operating profit 484.21 403.89
of Business Operation for the 3rd quarter of 2017 Bangchak Corporation Plc. Summary of the Company and its subsidiaries’ operating result for the 3rd quarter ended 30th September 2017 EBITDA Structure
Microsoft Word - MD฿A ประจำปี 2560_E 1 -1- Management Discussion and Analysis for the Year 2017 1. Operating Results (Company and Subsidiaries) Consolidated revenue for the twelve months of year 2017
contraction led to the decline in manufacturing production and private investment. Together with uncertainties in the trade relationship, weaker global economy, and the Thai Baht’s depreciation. On the domestic
or “SORKON” and its subsidiaries (“the company”) would like to clarify the operating results for Quarter 2/2019 as follows: Revenue and Net Sales The Company recorded its total revenue of Baht 728.8
Stock Exchange of Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the three-month period at the end of 30th September 2018 as